HEMOFİLİ A HASTALIĞININ MOLEKÜLER GENETİK TEMELLERİ

Year 2002, Volume: 3 Issue: 3, 43 - 47, 01.12.2002

Cemal Ün

Abstract

-

Keywords

Hemofili A, , Mutasyon, Gen terapisi

Molecular genetic fundaments of Haemophilia A disease

Abstract

Haemophilia A, with a prevalence of 1 in 10.000 is caused by a deficiency of blood coagulation factor VIII (FVIII). Haemophilia A is categorized into severe, moderate, or mild forms, with over half of the patients manifesting the severe disease. The factor VIII gene is extremely large (~ 180 kb) and structurally complex (26 exons). FVIII gene is located towards the end of the long arm at Xq28. Current treatment of haemophilia A is directed toward replacing the missing clotting factor in response to bleeding crises with infusions of plasma-derived or recombinant FVIII. Considerable progress has been made recently in the development of adenoviral-mediated in vivo and ex vivo gene therapy of haemophiliaA.

Keywords

Haemophilia A, , Mutation, Gene therapy

References

• 1. Kemball-Cook G, Tuddenham EG. The factor VIII mutation database on the World Wide Web: the haemophilia A mutation, search, test and resource site. NucleicAcids Res.1997;25:128-132.
• 2. Jacquemin M, Lavend'homme R, Benhida A, Vanzieleghem B, d'Oiron R, Lavergne JM, Brackmann HH, Schwaab R, VandenDriessche T, Marinee KL, Chuah, M H, Gilles JGG, Peerlinck J, Vermylen J, JeanMarie R, A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000;96: 958-965.
• 3. Timur AA, Gurgey A, Aktuglu G, Kavakli K, Canatan D, Olek K, Caglayan SH. Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations. Haemophilia 2001;7:475-81.
• 4. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani M, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne JM, Giannelli F, Antonarakis SE, Cooper DN Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res. 1994; 22:351-3.
• 5. Gitschier J, Wood W. I, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterisation of the human factor VIII gene. Nature 1984;312:326-30.
• 6. Becker J, Schwaab R, Möller-Taube A, Schwaab U, Schmidt W, Brackmann HH, Grimm T, Olek K , Oldenburg J Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation typedependent sex ratio of mutation frequencies. Am. J. Hum. Genet. 1996;58:657-670.
• 7. Lakich D, Kazazian HH jr,Antonarakis SE, Gitschier J. Inversions distrupting the factor VIII gene as a common cause of severe hemophilia A. Nat Genet 1993;5: 236-41.
• 8. Marco Leuer M, Oldenburg J, Lavergne JM, Ludwig M, Fregin A, Eigel A, Ljung R, Goodeve A, Peake I, Olek K. Somatic Mosaicism in Hemophilia A: A Fairly Common Event. Am. J. Hum. Genet. 2001;69: 75-87.
• 9. El-Maarri O, Kavakli K, Caglayan SH. Intron 22 inversions in the Turkish haemophilia A patients: prevalence and haplotype analysis. Haemophilia 1999 May;5(3):169-73.
• 10. Schneppenheim R, Budde U, Obser T, Brassard J, Mainusch K, Ruggeri ZM, Schneppenheim S, Oldenburg J, Schwaab R. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand dýsease. Blood 2001;97:2059-66.
• 11. Itin C, RocheA-C, Monsigny M, Hauri H-P ERGIC-53 is a functional mannose-selective and calciumdependent human homologue of leguminous lectins. Mol Biol Cell 1996;7:483.
• 12. Nichols WC, Seligsohn U, Zivelin A, Terry VH, Hertel CH, Wheatley MA, Moussali MJ, Hauri HP, Ciavarella N, Kaufman RJ, Ginsburg D. Mutations in the ERGolgi Intermediate Compartement protein ERGIC-53 Cause Combined Deficiency of Coagulation Factors V and VIII. Cell 1998;93: 61-70.
• 13. Schwaab R, Albert T, Brackmann HH, Srour M, Oldenburg J. Gentherapie der Hämophilie. Biospektrum. 2002;2:2-8.
• 14. Connelly S Andrews JL Gallo AM Kayda DB Qian J Hoyer L Kadan MJ Gorziglia MI Trapnell BC McClelland A Kaleko M Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy. Blood1 998;91: 3273-3281.
• 15. Sarkar R, Gao GP, Chirmule N, Tazelaar J, Kazazian HH Jr. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum. Gene. Ther. 2000;11(6):881-94.
• 16. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, McClelland A, Lothrop CD Jr. Complete shortterm correction of canine hemophilia A by in vivo gene therapy. Blood 1996;88:3846-3853.
• 17. Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C, Hough C, Notley C, Lillicrap D, Kaleko M, Connelly S.Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia Adogs. Blood 2001;97:107-113.
• 18. Saenko EL, Scandella D.AMechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J. Biol. Chem. 1995;270:13826-13833.
• 19. Naylor J, Brinke A, Hassock S, Green P, Giannelli F. Characteristic mRNA abnormality found in half the patients with severe haemophilia Ais due to large DNA inversions. Hum. Mol. Genet. 1993;2(11):1773-1778.
• 20. Cutler JA, Mitchell MJ, Smith MP, Savidge GF The identification and classification of 41 Novel Mutations in the Factor VIII gene (F8C). Human Mutation 2002; 19:274-278.
• 21. Bagnall RD, Waseem N, Green PM, Gianelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood 2002;99:168-174.
• 22 Lalloz MR, Schwaab R, McVey JH, Michaelides K, Tuddenham EG. Haemophilia A diagnosis by analysis of a novel dinucleotide tandem repeat sequence within the factor VIII gene. Br. J. Haematol. 1994;86(4):804- 809.
• 23. Lalloz MR, McVey JH, Pattinson JK, Tuddenham, EG. HaemophiliaAdiagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. Lancet 1991;338:20711.
• 24. Wong C, Dowling CD, Saiki RK, Higuchi RG, Erlich H, Kazazian HH. Characterization of betathalassaemia mutations using direct genomic sequencing of amplified single copy DNA. Nature 1987;330: 384-386.
• 25. Higuchi M, Antonarakis SE, Kasch L, Oldenburg J, Economou-Petersen E, Olek, K, Arai M, Inaba H, Kazazian HH Molecular characterization of mild-tomoderate hemophiliaA: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc. Natl. Acad. Sci. U S A. 1991;88(19):8307-8311.
• 26. Higuchi M, Wong C, Kochhan L, Olek K, Aronis S, Kasper CK, Kazazian HH, Antonarakis SE. Characterization of mutations in the factor VIII gene by direct sequencing of amplified genomic DNA. Genomics 1990;6: 65-71.
• 27. Waseem NH, Bagnall R, Green PM, Gianelli F. Start of UK confidential haemophilia A database: analysis of 142 patients by solid phase fluorescent chemical cleavage of mismatch. Haemophilia centres. Thromb. Haemost. 1999;81:900-905.
• 28. Orita M, Iwahana H, Kanazawa H. Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. USA. 1989;86:276-670.
• 29. Uen C, Klopp N, Oldenburg J, Brackmann HH, SchrammW, Schwaab R, Graw J. 11 novel mutations in the Factor VIII encoding gene lead to severe or moderate Hemophilia A. in: 32 Hemophilia Symposium Hamburg 2001; eds: Scharrer, I., Schramm,W., , 2002; in press.
• 30. Lalloz MRA, Schwaab R, McVey JH, Michaelides K, Tuddenham EG Hemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene. Br. J. Haematol. 1994;86:8049.
• 31. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitorstwenty years Bonn protocol. Vox Sang 1996Ê;70 (suppl):30-35.
• 32. Hoeben RC, Fallaux FJ, Cramer SJ. Expression of the blood-clotting factor-VIII cDNA is repressed a transcriptional silencer located in its coding region. Blood 1995;85:2447-2454.
• 33. Connely S, Smith TAG, Dhir G, Gardner JM, Mehaffey MG, Zarte KS, McCleelland A, Kaleko M. In vivo delivery and expression of physiological levels of functional human factor VIII in mice. Hum. Gen. Ther. 1995;6: 185-193.
• 34. Graw J, Klopp N, Brackmann HH, Schwaab R,Oldenburg J, Schramm W. Genotyp-Phenotypkorrelation bei der Hämophilia A. Biospektrum. 2001;3:217-219.